Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| Yesterday 6:00 PM View:  | Readnour Robin Shane Director | An2 Therapeutics, Inc. (ANTX) | 20-Nov-24 | Purchase | 50,000 | $1.16 | $57,870.00 | 5% 1.05M to 1.1M | |
| Yesterday 6:00 PM View: | Readnour Robin Shane Director | An2 Therapeutics, Inc. (ANTX) | 19-Nov-24 | Private Purchase | 150,000 | $1.04 | $155,257.00 | 17% 899.86K to 1.05M | |
| 20-Nov-24 4:11 PM View: | Zakrzewski Joseph S Director | An2 Therapeutics, Inc. (ANTX) | 19-Nov-24 | Purchase | 5,000 | $1.01 | $5,050.00 | < 1% 524.08K to 529.08K | |
| 20-Nov-24 4:11 PM View: | Zakrzewski Joseph S Director | An2 Therapeutics, Inc. (ANTX) | 18-Nov-24 | Private Purchase | 20,000 | $1.00 | $19,996.00 | 4% 504.08K to 524.08K | |
| 18-Nov-24 8:51 PM View: | Easom Eric Chief Executive Officer Director | An2 Therapeutics, Inc. (ANTX) | 18-Nov-24 | Private Purchase | 50,000 | $1.00 | $49,970.00 | 4% 1.31M to 1.36M | |
| 14-Aug-24 8:24 PM View: | Leonard Braden Michael 10% Owner | An2 Therapeutics, Inc. (ANTX) | 14-Aug-24 | Private Purchase | 1,500,000 | $1.04 | $1,560,000.00 | 35% 4.25M to 5.75M | |
| 13-Aug-24 5:03 PM View: | Ra Capital Management, LLC 10% Owner | An2 Therapeutics, Inc. (ANTX) | 09-Aug-24 | Sale | 3,525,090 | $1.08 | $3,807,100.00 | (64%) 5.55M to 2.03M | |
| 12-Jul-24 4:13 PM View: | Eizen Joshua M Chief Legal Officer | An2 Therapeutics, Inc. (ANTX) | 10-Jul-24 | Grant | 60,000 | -- | -- | 172% 34.83K to 94.83K | |
| 18-Mar-24 7:26 PM View: | Easom Eric Chief Executive Officer Director | An2 Therapeutics, Inc. (ANTX) | 15-Mar-24 | Grant | 99,000 | -- | -- | 8% 1.21M to 1.31M | |
| 18-Mar-24 7:29 PM View: | Day Lucy Chief Financial Officer | An2 Therapeutics, Inc. (ANTX) | 15-Mar-24 | Grant | 27,500 | -- | -- | 879% 3.13K to 30.63K | |
| 18-Mar-24 7:28 PM View: | Eizen Joshua M Chief Legal Officer | An2 Therapeutics, Inc. (ANTX) | 15-Mar-24 | Grant | 30,000 | -- | -- | 1226% 2.45K to 32.45K | |
| 18-Mar-24 7:28 PM View: | Krause Kevin Michael Chief Strategy Officer | An2 Therapeutics, Inc. (ANTX) | 15-Mar-24 | Grant | 30,000 | -- | -- | 1567% 1.91K to 31.91K | |
| 18-Mar-24 7:27 PM View: | Eckburg Paul Chief Medical Officer | An2 Therapeutics, Inc. (ANTX) | 15-Mar-24 | Grant | 30,000 | -- | -- | 140% 21.42K to 51.42K | |
| 18-Mar-24 7:27 PM View: | Chanda Sanjay Chief Development Officer | An2 Therapeutics, Inc. (ANTX) | 15-Mar-24 | Grant | 27,500 | -- | -- | 3742% 0.73K to 28.23K | |
| 19-Jan-24 7:32 PM View: | Zakrzewski Joseph S Director | An2 Therapeutics, Inc. (ANTX) | 18-Jan-24 | Private Sale | 100,000 | $19.11 | $1,911,410.00 | (17%) 604.08K to 504.08K | |
| 18-Jan-24 6:18 PM View: | Adjuvant Global Health Tech... 10% Owner | An2 Therapeutics, Inc. (ANTX) | 16-Jan-24 | Private Sale | 84,093 | $19.65 | $1,652,430.00 | (3%) 2.47M to 2.39M | |
| 18-Jan-24 6:19 PM View: | Aziz Kabeer Director | An2 Therapeutics, Inc. (ANTX) | 16-Jan-24 | Private Sale | 100,000 | $19.65 | $1,965,000.00 | (4%) 2.47M to 2.37M | |
| 18-Jan-24 6:18 PM View: | Adjuvant Global Health Tech... 10% Owner | An2 Therapeutics, Inc. (ANTX) | 16-Jan-24 | Sale | 15,907 | $19.65 | $312,573.00 | (< 1%) 2.39M to 2.37M | |
| 17-Jan-24 5:03 PM View: | Readnour Robin Shane Director | An2 Therapeutics, Inc. (ANTX) | 12-Jan-24 | Private Sale (Planned) | 1,425 | $21.92 | $31,228.80 | (< 1%) 901.29K to 899.86K | |
| 12-Jan-24 5:08 PM View: | Readnour Robin Shane Director | An2 Therapeutics, Inc. (ANTX) | 10-Jan-24 | Private Sale (Planned) | 3,669 | $21.93 | $80,443.20 | (< 1%) 904.96K to 901.29K | |
| 11-Jan-24 7:59 PM View: | Krause Kevin Michael Chief Strategy Officer | An2 Therapeutics, Inc. (ANTX) | 09-Jan-24 | Option Exercise | 7,417 | $4.59 | $34,015.10 | 388% 1.91K to 9.33K | |
| 11-Jan-24 7:59 PM View: | Krause Kevin Michael Chief Strategy Officer | An2 Therapeutics, Inc. (ANTX) | 09-Jan-24 | Planned Option Sale | 7,417 | $20.14 | $149,367.00 | (79%) 9.33K to 1.91K | |
| 04-Jan-24 6:06 PM View: | Krause Kevin Michael Chief Strategy Officer | An2 Therapeutics, Inc. (ANTX) | 02-Jan-24 | Planned Option Sale | 2,583 | $20.12 | $51,967.10 | (57%) 4.5K to 1.91K | |
| 04-Jan-24 6:05 PM View: | Easom Eric Chief Executive Officer Director | An2 Therapeutics, Inc. (ANTX) | 02-Jan-24 | Private Sale (Planned) | 2,777 | $20.09 | $55,802.40 | (< 1%) 1.21M to 1.21M | |
| 04-Jan-24 6:06 PM View: | Krause Kevin Michael Chief Strategy Officer | An2 Therapeutics, Inc. (ANTX) | 02-Jan-24 | Option Exercise | 2,583 | $0.42 | $1,084.86 | 135% 1.91K to 4.5K | |
| 16-Nov-23 6:57 PM View: | Aziz Kabeer Director 10% Owner | An2 Therapeutics, Inc. (ANTX) | 14-Nov-23 | Market Sale (Planned) | 1,810 | $16.15 | $29,224.30 | (< 1%) 2.48M to 2.47M | 7% |
| 16-Nov-23 6:59 PM View: | Adjuvant Global Health Tech... 10% Owner | An2 Therapeutics, Inc. (ANTX) | 14-Nov-23 | Market Sale (Planned) | 1,522 | $16.15 | $24,574.20 | (< 1%) 2.48M to 2.47M | 7% |
| 16-Nov-23 6:59 PM View: | Adjuvant Global Health Tech... 10% Owner | An2 Therapeutics, Inc. (ANTX) | 14-Nov-23 | Market Sale (Planned) | 288 | $16.15 | $4,650.05 | (< 1%) 2.47M to 2.47M | 7% |
| 03-Oct-23 10:00 PM View: | Adjuvant Global Health Tech... 10% Owner | An2 Therapeutics, Inc. (ANTX) | 02-Oct-23 | Sale (Planned) | 902 | $16.07 | $14,495.10 | (< 1%) 2.48M to 2.48M | |
| 03-Oct-23 10:00 PM View: | Adjuvant Global Health Tech... 10% Owner | An2 Therapeutics, Inc. (ANTX) | 02-Oct-23 | Sale (Planned) | 4,770 | $16.07 | $76,653.90 | (< 1%) 2.48M to 2.48M | |
| 03-Oct-23 10:00 PM View: | Aziz Kabeer Director 10% Owner | An2 Therapeutics, Inc. (ANTX) | 02-Oct-23 | Sale (Planned) | 5,672 | $16.07 | $91,149.00 | (< 1%) 2.48M to 2.48M | |
| 03-Oct-23 10:00 PM View: | Adjuvant Global Health Tech... 10% Owner | An2 Therapeutics, Inc. (ANTX) | 29-Sep-23 | Private Sale (Planned) | 83,337 | $16.28 | $1,356,730.00 | (3%) 2.58M to 2.5M | |
| 03-Oct-23 10:00 PM View: | Adjuvant Global Health Tech... 10% Owner | An2 Therapeutics, Inc. (ANTX) | 29-Sep-23 | Sale (Planned) | 15,764 | $16.28 | $256,638.00 | (< 1%) 2.5M to 2.48M | |
| 03-Oct-23 10:00 PM View: | Aziz Kabeer Director 10% Owner | An2 Therapeutics, Inc. (ANTX) | 29-Sep-23 | Private Sale (Planned) | 99,101 | $16.28 | $1,613,360.00 | (4%) 2.58M to 2.48M | |
| 29-Sep-23 5:40 PM View: | Aziz Kabeer Director 10% Owner | An2 Therapeutics, Inc. (ANTX) | 28-Sep-23 | Market Sale (Planned) | 8,516 | $16.11 | $137,193.00 | (< 1%) 5.18M to 5.17M | 7% |
| 29-Sep-23 5:41 PM View: | Adjuvant Global Health Tech... 10% Owner | An2 Therapeutics, Inc. (ANTX) | 28-Sep-23 | Market Sale (Planned) | 7,160 | $16.11 | $115,348.00 | (< 1%) 2.59M to 2.58M | 7% |
| 29-Sep-23 5:41 PM View: | Adjuvant Global Health Tech... 10% Owner | An2 Therapeutics, Inc. (ANTX) | 28-Sep-23 | Market Sale (Planned) | 1,356 | $16.11 | $21,845.20 | (< 1%) 2.58M to 2.58M | 7% |
| 29-Sep-23 5:41 PM View: | Adjuvant Global Health Tech... 10% Owner | An2 Therapeutics, Inc. (ANTX) | 27-Sep-23 | Market Sale (Planned) | 707 | $16.07 | $11,361.50 | (< 1%) 2.59M to 2.59M | 7% |
| 29-Sep-23 5:40 PM View: | Aziz Kabeer Director 10% Owner | An2 Therapeutics, Inc. (ANTX) | 27-Sep-23 | Market Sale (Planned) | 841 | $16.07 | $13,514.90 | (< 1%) 5.18M to 5.18M | 7% |
| 29-Sep-23 5:41 PM View: | Adjuvant Global Health Tech... 10% Owner | An2 Therapeutics, Inc. (ANTX) | 27-Sep-23 | Market Sale (Planned) | 134 | $16.07 | $2,153.38 | (< 1%) 2.59M to 2.59M | 7% |
| 15-Sep-23 5:17 PM View: | Adjuvant Global Health Tech... 10% Owner | An2 Therapeutics, Inc. (ANTX) | 13-Sep-23 | Market Sale (Planned) | 64 | $16.00 | $1,024.00 | (< 1%) 2.59M to 2.59M | 6% |
| 15-Sep-23 5:40 PM View: | Aziz Kabeer Director 10% Owner | An2 Therapeutics, Inc. (ANTX) | 13-Sep-23 | Market Sale (Planned) | 400 | $16.00 | $6,400.00 | (< 1%) 2.59M to 2.59M | 6% |
| 15-Sep-23 5:17 PM View: | Adjuvant Global Health Tech... 10% Owner | An2 Therapeutics, Inc. (ANTX) | 13-Sep-23 | Market Sale (Planned) | 336 | $16.00 | $5,376.00 | (< 1%) 2.59M to 2.59M | 6% |
| 08-Sep-23 4:57 PM View: | Aziz Kabeer Director 10% Owner | An2 Therapeutics, Inc. (ANTX) | 07-Sep-23 | Market Sale (Planned) | 3,378 | $16.05 | $54,216.90 | (< 1%) 2.59M to 2.59M | 6% |
| 08-Sep-23 4:59 PM View: | Adjuvant Global Health Tech... 10% Owner | An2 Therapeutics, Inc. (ANTX) | 07-Sep-23 | Market Sale (Planned) | 2,841 | $16.05 | $45,598.00 | (< 1%) 2.59M to 2.59M | 6% |
| 08-Sep-23 4:59 PM View: | Adjuvant Global Health Tech... 10% Owner | An2 Therapeutics, Inc. (ANTX) | 07-Sep-23 | Market Sale (Planned) | 537 | $16.05 | $8,618.85 | (< 1%) 2.59M to 2.59M | 6% |
| 08-Sep-23 4:59 PM View: | Adjuvant Global Health Tech... 10% Owner | An2 Therapeutics, Inc. (ANTX) | 06-Sep-23 | Market Sale (Planned) | 3,164 | $16.02 | $50,687.30 | (< 1%) 2.6M to 2.59M | 6% |
| 08-Sep-23 4:57 PM View: | Aziz Kabeer Director 10% Owner | An2 Therapeutics, Inc. (ANTX) | 06-Sep-23 | Market Sale (Planned) | 3,762 | $16.02 | $60,267.20 | (< 1%) 2.6M to 2.59M | 6% |
| 08-Sep-23 4:59 PM View: | Adjuvant Global Health Tech... 10% Owner | An2 Therapeutics, Inc. (ANTX) | 06-Sep-23 | Market Sale (Planned) | 598 | $16.02 | $9,579.96 | (< 1%) 2.59M to 2.59M | 6% |
| 25-Aug-23 4:31 PM View: | Adjuvant Global Health Tech... 10% Owner | An2 Therapeutics, Inc. (ANTX) | 23-Aug-23 | Market Sale | 64 | $16.00 | $1,024.00 | (< 1%) 2.6M to 2.6M | 6% |
